Welcome to our dedicated page for Scorpius Holdings SEC filings (Ticker: SCPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a contract developer like Scorpius Holdings Inc. (SCPX) scales its cGMP suites or lands government bio-security contracts often means wading through hundreds of pages of technical SEC disclosures. Capacity additions are buried in a footnote, and executive stock awards hide in dense tables. If you have ever wondered, “Where are Scorpius Holdings insider trading Form 4 transactions reported?” or “How can I read the Scorpius Holdings quarterly earnings report 10-Q filing without a PhD in bioprocessing?” this page was built for you.
Stock Titan’s AI parses every document the moment it hits EDGAR, then delivers clear, plain-English answers. You’ll see real-time alerts on Scorpius Holdings Form 4 insider transactions, red-flag summaries of any 8-K material events, and capacity-utilization callouts pulled straight from the MD&A. Our platform links each highlight back to the source page so you can verify figures fast, making understanding Scorpius Holdings SEC documents with AI both accurate and efficient.
Whether you need the Scorpius Holdings annual report 10-K simplified, a side-by-side view of segment margins from the latest Scorpius Holdings earnings report filing analysis, or details on the Scorpius Holdings proxy statement executive compensation, every filing type—10-Q, 8-K, S-8, DEF 14A—lives here with AI-powered context. Use it to monitor facility build-out costs before dilution events, compare quarter-over-quarter backlog trends, or get instant alerts on Scorpius Holdings executive stock transactions Form 4. Complex biotech disclosures, finally clear.
Redmile Group, LLC, Jeremy C. Green and RedCo II Master Fund, L.P. have filed Amendment No. 9 to their Schedule 13D on Fate Therapeutics, Inc. (NASDAQ: FATE). The filing, triggered by an event dated 07 July 2025, updates the group’s ownership disclosure and key blocking provisions.
- Aggregate beneficial ownership: 17,941,579 common shares (direct and deemed) representing 14.9 % of FATE’s outstanding common stock (114,633,022 shares as of 6 May 2025).
- Key holder detail: RedCo II Master Fund holds 13,479,013 shares (11.3 %). All shares are subject to shared voting and dispositive power; no reporting person has sole power.
- Warrants & preferred stock: • Pre-Funded Warrants covering 3,691,324 shares (exercise price $0.001) • Class A Preferred Stock convertible 1-for-5 into up to 810,065 shares (RedCo II) and additional preferred shares across other Redmile funds.
Both instruments are governed by 14.99 % beneficial-ownership blockers. - Change in blocker threshold: On 1 July 2025 Redmile elected to raise the “Maximum Percentage” under the Warrant Beneficial Ownership Blocker from 9.99 % to 14.99 % (effective 61 days later). This allows the group to exercise additional warrants and approach the new 14.99 % cap without breaching Section 13(d) limits.
- Funding source: Working capital of various Redmile-managed private investment funds (no external financing disclosed).
- Historical context: This is the ninth amendment to an initial 13D filed in 2018, reflecting the evolution of Redmile’s position and security mix (common, warrants, preferred, options, RSUs).
The amendment does not announce new purchases or sales but formalises the larger ownership cap, clarifies the composition of the beneficial stake, and reiterates blocker mechanics designed to limit ownership to 14.99 % of outstanding commons.
Scorpius Holdings (NASDAQ:SCPX) filed an 8-K reporting that on June 18, 2025 it entered into a short-term financing arrangement via a $130,000 non-convertible promissory note (the “Note”) with an institutional investor.
The Note carries 5.0% annual interest and becomes due on the earliest of: (i) July 31, 2025; (ii) completion of a defined corporate event; or (iii) an event of default. Default events include failure by the company or its subsidiaries to pay indebtedness exceeding $150,000 or default on any other outstanding notes. Should Scorpius complete a subsequent financing while the Note is outstanding, the holder may, at its discretion, require redemption of the full outstanding balance—up to 100% of the gross proceeds of such financing.
The Note was issued under Section 4(a)(2) and/or Regulation D exemptions, meaning the securities are restricted and not registered with the SEC. The disclosure triggers three 8-K items: Item 1.01 (material definitive agreement), Item 2.03 (creation of a direct financial obligation), and Item 3.02 (unregistered sales of securities). A copy of the Note is filed as Exhibit 4.1.
No additional financial statements, risk factors or legal proceedings were included. The filing principally signals a near-term liquidity action and introduces customary covenants that could accelerate repayment if certain events occur.
FAQ
What is the current stock price of Scorpius Holdings (SCPX)?
What is the market cap of Scorpius Holdings (SCPX)?
What is the primary business of Scorpius Holdings?
How does Scorpius Holdings generate revenue?
What are the core service areas of the company?
How does Scorpius Holdings differentiate itself in the competitive CDMO industry?
How does the company contribute to public health and biosecurity initiatives?
What role do strategic partnerships play in Scorpius Holdings' operations?
How are quality and regulatory standards maintained at Scorpius Holdings?
What makes Scorpius Holdings a trusted partner for its clients?
